BLOOMFIELD, Conn., June 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2.Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an integrated downstream energy company, and MPLX, a diversified master limited partnership formed by MPC. He joined the company in 2017 and previously held the roles of Chief Executive Officer of M ...

Group 1: Company Overview - UnitedHealth is experiencing short-term pressure due to rising medical utilization and changes in CMS models, but its long-term growth thesis remains strong [1] - The Medicare Advantage business of UnitedHealthcare is projected to serve an additional 800,000 people in FY 2025 [1] Group 2: Investment Strategy - The investment methodology focuses on identifying high-conviction opportunities with a strong emphasis on leadership, market disruption, financial health, and valuation [1] - Core positions (50-70%) are allocated to high-confidence, stable plays, while growth bets (20-40%) are high-risk, high-reward opportunities, and speculative investments (5-10%) are aimed at moonshot disruptors [1]

Key Takeaways CI is up 14.7% YTD, outperforming the industry's 29.1% drop, backed by dual-segment strength. Evernorth revenues rose 16% to $53.7B in Q1 2025; Cigna Healthcare grew 9% year over year. CI faces margin pressure from rising benefit costs and carries $26.5B in long-term debt.The Cigna Group (CI) , a longstanding global health company, continues to offer a variety of health solutions and insurance products. It operates through two main divisions: Cigna Healthcare and Evernorth Health Services. T ...

Financial Data and Key Metrics Changes - The company acknowledges that it has not fulfilled shareholder expectations and is committed to restoring performance [25][26] - The stock price has declined from $630 in 2024 to $315 currently, indicating significant market challenges [11] Business Line Data and Key Metrics Changes - The management team is focusing on improving pricing disciplines and forecasting accuracy for care and financial activity [27][28] - OptumHealth is emphasized as a critical area for evolving American healthcare from a fee-for-service model to value-based care [29][30] Market Data and Key Metrics Changes - The company is actively addressing care activity and cost trends that have led to outsized growth, indicating a need for better market alignment [27][28] Company Strategy and Development Direction - The company is undergoing a comprehensive review of operations to enhance performance and transparency [26][30] - New initiatives are being introduced to improve risk assessment, coding practices, and compliance measures [30][31] - The company aims to reinvigorate its performance culture and maintain a lean operational structure while investing in stakeholders [31][32] Management's Comments on Operating Environment and Future Outlook - Management expresses a commitment to restoring trust and confidence among shareholders and acknowledges past performance shortcomings [25][26] - A prudent earnings outlook for 2025 will be established in the upcoming second-quarter report, with initial perspectives for 2026 [31] Other Important Information - The company has received advisory approval for executive compensation and ratified the appointment of Deloitte and Touche LLP as the independent auditor for the fiscal year [22] Q&A Session Summary Question: Will you provide specific data on the factors used by AI in denying care that overrides physician/provider team assessment? - The company clarifies that AI is used to support providers and reduce administrative burdens, not to deny care [36][37] Question: Is there a retirement age for UNH directors? - The company does not have a hard policy but follows guidelines that suggest a retirement age of about 75 [38] Question: How long will it take the company to get back to normal margins on the MA business? Could this be fixed in twelve to eighteen months? - The company has suspended guidance and will not respond to financial questions until guidance is reestablished on July 29 [39] Question: Can you provide an update on your knowledge regarding government investigations? - The company will not comment on open investigations but assures that material matters will be disclosed in SEC filings [40][41]

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose adverse facts regarding its business operations and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Financial Performance - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, which led to a stock price drop of $32.21, or 5.8%, closing at $520.93 per share [2]. - On October 17, 2024, Elevance reported third quarter 2024 financial results, missing EPS consensus estimates by 13.7% and lowering its EPS guidance for 2024 by 11.3%, resulting in a further stock price decline of $52.61, or 10.6%, to close at $444.35 per share [3]. Lawsuit Details - The class action complaint alleges that Elevance's management made materially false and misleading statements and failed to disclose significant adverse facts, including the higher costs associated with sicker patients remaining on Medicaid and inadequate reflection of these costs in financial guidance [4]. - Investors who purchased Elevance common stock during the Class Period have until July 11, 2025, to file a lead plaintiff motion in the lawsuit [5].

Core Insights - UnitedHealth Group Inc (NYSE:UNH) has experienced a significant decline of 39.1% year-to-date in 2025, primarily due to rising medical costs and the unexpected departure of CEO Andrew Witty [1] - Despite the challenges, options trading activity remains robust, with a notable volume of both calls and puts in recent trading sessions [2] Options Trading Activity - Over the last 10 trading days, UnitedHealth recorded a total of 4,843,914 options, comprising 3,313,688 calls and 1,530,226 puts [2][3] - The most popular options contract was the weekly 5/23 300-strike call, indicating strong interest among traders [2] Stock Performance - UnitedHealth shares were last observed at $307.50, reflecting a 1.9% increase and marking a potential fourth consecutive daily gain [5] - The stock is attempting to recover from a significant dip to $269.13 on May 16, which was its lowest level since April 2020 [5] Volatility Metrics - The Schaeffer's Volatility Scorecard (SVS) for UnitedHealth ranks at 95 out of 100, suggesting that the stock typically exceeds options traders' annual volatility expectations [7]

Core Insights - UnitedHealth Group Incorporated (UNH) shares have dropped 25.4% in the past month, resulting in a year-to-date loss of 40.4%, significantly underperforming both the broader industry and the S&P 500 [1][7] - The company is facing multiple pressures, including rising medical costs, missed earnings and revenue estimates, and a withdrawal of its 2025 financial guidance [4][15] - Investor sentiment is deteriorating, with numerous downward revisions to earnings estimates for 2025 and 2026, despite projected revenue growth [7][8] Financial Performance - UnitedHealth generated $5.5 billion in operating cash flow in the first quarter, a substantial increase from $1.1 billion the previous year, and ended the quarter with $34.3 billion in cash and short-term investments [14] - The Zacks Consensus Estimate for UNH's 2025 EPS has seen 12 downward revisions, projecting a decline of 17.3%, while revenues are expected to increase by 12.9% year over year [7][8] Market Position and Valuation - UNH is trading at a forward P/E of 12.31X, below its five-year median of 19.20X but above the industry average of 11.50X, indicating a mixed valuation perspective [8][10] - Despite appearing attractively priced, regulatory risks, cost pressures, and reputational damage pose significant threats to the company's business model [10][15] Competitive Advantages - UnitedHealth retains competitive advantages through its vertically integrated model, scale, and investments in AI and digital health, which may help navigate long-term industry trends [12] - The company served 50.1 million members as of March 31, 2025, reflecting a 1.9% year-over-year growth, driven by self-funded commercial plans [13] Outlook and Recommendations - The near-term outlook for UnitedHealth is clouded by setbacks, including regulatory probes and leadership changes, which have undermined investor confidence [15][16] - With no clear catalysts for recovery and significant underperformance, it may be prudent for investors to wait for signs of stabilization before re-entering [16]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including administering Medicaid benefits, which were affected by a federal pause on eligibility reviews during COVID-19 [3]. - Following the end of the pause in 2023, states resumed redetermining Medicaid eligibility, which led to significant increases in acuity and utilization among Elevance's Medicaid members [5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate [4]. - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, causing a further stock decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - A class action securities lawsuit has been filed against UnitedHealth Group Incorporated, alleging securities fraud that adversely affected investors between December 3, 2024, and April 16, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3]. - This strategy led to regulatory scrutiny and public outrage, culminating in the murder of Brian Thompson, which further damaged the company's reputation [3]. - Following the murder, there was significant animosity towards UnitedHealth, with many Americans expressing support for the accused killer and demanding changes in the company's practices [3]. - Despite the backlash, UnitedHealth continued to adhere to its previous guidance, which was deemed unrealistic given the changing corporate strategies [3]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until July 7, 2025, to request appointment as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in UnitedHealth Group Incorporated ("UnitedHealth Group Incorporated" or the "Company") (NYSE: UNH) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UnitedHealth Group Incorporated investors who were adversely affected by alleged securities fraud between December 3, 2024 and April 16, 2025. Follow the link below to get more information and be contacted by a member of our tea ...